Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-56743
Chirgwin, J; Sun, Z; Smith, I; Price, K N; Thürlimann, B; Ejlertsen, B; Bonnefoi, H; Regan, M M; Goldhirsch, A; Coates, A S (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131(1):295-306.
PDF - Registered users only
Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subclinical ovarian estrogen production), and those with chemotherapy-induced menopause who may experience return of ovarian function. In these situations tamoxifen may be preferable to an aromatase inhibitor. Among 4,922 patients allocated to the monotherapy arms (5 years of letrozole or tamoxifen) in the BIG 1-98 trial we identified two relevant subpopulations: patients with potential residual ovarian function, defined as having natural menopause, treated without adjuvant or neoadjuvant chemotherapy and age ≤ 55 years (n = 641); and those with chemotherapy-induced menopause (n = 105). Neither of the subpopulations examined showed treatment effects differing from the trial population as a whole (interaction P values are 0.23 and 0.62, respectively). Indeed, both among the 641 patients aged ≤ 55 years with natural menopause and no chemotherapy (HR 0.77 [0.51, 1.16]) and among the 105 patients with chemotherapy-induced menopause (HR 0.51 [0.19, 1.39]), the disease-free survival (DFS) point estimate favoring letrozole was marginally more beneficial than in the trial as a whole (HR 0.84 [0.74, 0.95]). Contrary to our initial concern, DFS results for young postmenopausal patients who did not receive chemotherapy and patients with chemotherapy-induced menopause parallel the letrozole benefit seen in the BIG 1-98 population as a whole. These data support the use of letrozole even in such patients.
|Contributors:||Varga Z, Caduff R|
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology|
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
|DDC:||610 Medicine & health|
|Deposited On:||16 Feb 2012 14:21|
|Last Modified:||08 Dec 2013 06:58|
|ISSN:||0167-6806 (P) 1573-7217 (E)|
|Citations:||Web of Science®. Times Cited: 3|
Scopus®. Citation Count: 4
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page